Cipro uti dosage

Posted: shizurik On: 11-Feb-2019
Ciprofloxacin <strong>Cipro</strong> - Side Effects, <strong>Dosage</strong>, Interactions - Drugs

Ciprofloxacin Cipro - Side Effects, Dosage, Interactions - Drugs

What is a UTI | Which antibiotic to use | Common side effects | Antibiotic resistance | New antibiotics | OTC antibiotics | Recurring UTIs | Treatment without antibiotics | Cranberry juice | More resources If you have ever experienced the frequent urge to go the bathroom with painful burning urination, you have probably experienced a urinary tract infection (UTI). You may be surprised to know that UTIs are the second most common type of infection in the body, accounting for over 8 million visits to health care providers each year. Sometimes a UTI can be self-limiting, meaning that your body can fight the infection without antibiotics; however, most uncomplicated UTI cases can be treated quickly with a short course of oral UTI antibiotics. A UTI infection can happen anywhere along your urinary tract, which includes the kidneys (the organ that filters the blood to make urine), the ureters (the tubes that take urine from each kidney to the bladder), the bladder (stores urine), or the urethra (the tube that empties urine from the bladder to the outside). A lower urinary tract infection occurs when bacteria gets into the urethra and is deposited up into the bladder -- this is called cystitis. Infections that get past the bladder and up into the kidneys are called pyelonephritis . An infection of the tube that empties urine from the bladder to the outside is called urethritis. Urinary tract infection symptoms may include: Upper UTIs which include the kidney may also have symptoms of fever, back pain, and nausea or vomiting. The determination of dosage and duration for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative microorganism, the integrity of the patient’s host-defense mechanisms, and the status of renal and hepatic function. CIPRO Tablets or Oral Suspension may be administered to adult patients when clinically indicated at the discretion of the physician. Administer CIPRO for Oral Suspension using the co-packaged graduated spoon Dosing and initial route of therapy (that is, IV or oral) for c UTI or pyelonephritis should be determined by the severity of the infection. CIPRO should be administered as described in Table 3. Administer CIPRO for Oral Suspension using the co-packaged graduated spoon Ciprofloxacin is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternative pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. Nonetheless, some modification of dosage is recommended, particularly for patients with severe renal dysfunction.

Ciprofloxacin <i>Dosage</i> Guide with Precautions -

Ciprofloxacin Dosage Guide with Precautions -

UTI symptoms in women may include vaginal discharge, especially if the urethra is infected, or if an STD is involved. Ciprofloxacin and UTIs Many medical experts support using ciprofloxacin (Cipro) as an alternative and, in some cases, as the preferred first-line antibiotic for UTI treatment. However, others caution that widespread use of fluoroquinolones will promote increased resistance. FDA for complicated UTIs and pyelonephritis in children. Ciprofloxacin is an attractive alternative to TMP-SMX due to its high concentrations in the urogenital tissues, activity against the full range of uropathogens, and well-established clinical efficacy. Ciprofloxacin is useful in treating complicated and uncomplicated cystitis, recurrent UTI, and kidney infection. Ciprofloxacin dosage for UTI Adults: 250 mg every 12 hours for 7 to 14 days. Complicated infections require 500 mg every 12 hours. Children 1-17 years of age: 10–20 mg/kg (up to 750 mg) every 12 hours for 10–21 days. Cystitis (bladder infection) in women: The usual dosage is 250 mg every 12 hours for 3 days. Cipro (ciprofloxacin) is a brand-name prescription antibiotic medication. Cipro belongs to a class of antibiotics called fluoroquinolones. Cipro is effective for treating infections caused by many different types of bacteria. These include bacteria that cause infections in the urinary tract, abdomen, skin, prostate, and bone, as well as other types of infections. Cipro comes in several forms: Cipro can cause mild or serious side effects. The following list contains some of the key side effects that may occur while taking Cipro. This list does not include all possible side effects. For more information on the possible side effects of Cipro, or tips on how to deal with a troubling side effect, talk with your doctor or pharmacist.

<strong>Cipro</strong> Side Effects, Uses, <strong>Dosage</strong>, and More - Healthline

Cipro Side Effects, Uses, Dosage, and More - Healthline

Mild/moderate: 500 mg PO q12hr or 400 mg IV q12hr for 7-14 days Severe/complicated: 750 mg PO q12hr or 400 mg IV q8hr for 7-14 days Limitations-of-use: Reserve fluoroquinolones for patients who do not have other available treatment options for acute bacterial exacerbation of chronic bronchitis Acute uncomplicated: Immediate-release, 250 mg PO q12hr for 3 days; extended-release, 500 mg PO q24hr for 3 days Mild/moderate: 250 mg PO q12hr or 200 mg IV q12hr for 7-14 days Severe/complicated: 500 mg PO q12hr or 400 mg IV q12hr for 7-14 days Limitations-of-use: Reserve fluoroquinolones for patients who do not have other available treatment options for uncomplicated urinary tract infections Dry powder for inhalation: Orphan designation for patients with NCFB who suffer from frequent severe acute pulmonary bacterial exacerbations which lead to further inflammation, airway, and lung parenchyma damage Indication for treatment and prophylaxis of plague due to Yersinia pestis in pediatric patients from birth to 17 years of age 15 mg/kg PO q8-12hr x10-21 days; not to exceed 500 mg/dose, OR 10 mg/kg IV q8-12hr x 10-21 days; not to exceed 400 mg/dose Postexposure therapy IV: 10 mg/kg q12hr for 60 days; individual dose not to exceed 400 mg PO: 15 mg/kg q12hr for 60 days; individual dose not to exceed 500 mg Change antibiotic to amoxicillin as soon as penicillin susceptibility confirmed Nausea (3%) Abdominal pain (2%) Diarrhea (2% adults; 5% children) Increased aminotransferase levels (2%) Vomiting (1% adults; 5% children) Headache (1%) Increased serum creatinine (1%) Rash (2%) Restlessness (1%) Acidosis Allergic reaction Angina pectoris Anorexia Arthralgia Ataxia Back pain Bad taste Blurred vision Breast pain Bronchospasm Diplopia Dizziness Drowsiness Dysphagia Dyspnea Flushing Foot pain Hallucinations Hiccups Hypertension Hypotension Insomnia Irritability Joint stiffness Lethargy Migraine Nephritis Nightmares Oral candidiasis Palpitation Photosensitivity Polyuria Syncope Tachycardia Tinnitus Tremor Urinary retention Vaginitis Acute generalized exanthematous pustulosis (AGEP), erythema multiforme, exfoliative dermatitis, fixed eruption, photosensitivity/phototoxicity reaction Agitation, confusion, delirium Agranulocytosis, albuminuria, serum cholesterol and TG elevations, blood glucose disturbances, hemolytic anemia, marrow depression (life threatening), pancytopenia (life threatening or fatal outcome), potassium elevation (serum) Anaphylactic reactions (including life-threatening anaphylactic shock), serum sickness like reaction, Stevens-Johnson syndrome Anosmia, hypesthesia Constipation, dyspepsia, dysphagia, flatulence, hepatic failure (including fatal cases), hepatic necrosis, jaundice, pancreatitis Hypertonia, hypotension (postural), increased INR (in patients treated with Vitamin K antagonists), QT prolongation, torsade de pointes, ventricular arrhythmia Methemoglobinemia Myasthenia, exacerbation of myasthenia gravis, myoclonus, nystagmus, peripheral neuropathy that may be irreversible, phenytoin alteration (serum), polyneuropathy, psychosis Myalgia, tendinitis, tendon rupture, toxic epidermal necrolysis (Lyell’s Syndrome), twitching Infections: Candiduria, vaginal candidiasis, moniliasis (oral, gastrointestinal, vaginal), pseudomembranous colitis Renal calculi Vasculitis Because the risk of these serious side effects generally outweighs the benefits for patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated UTIs, that fluoroquinolones should be reserved for use in patients with these conditions who have no alternative treatment options Use in pregnancy, though generally contraindicated for all quinolones, is allowed for life-threatening situations; limited data from use of ciprofloxacin in pregnancy show no higher rate of birth defects than background Do not use oral suspension in nasogastric tube; to prepare, add microcapsules to diluent Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion); these reactions can occur within hours to weeks after starting therapy, including in patients of any age or without pre-existing risk factors; discontinue therapy immediately at first signs or symptoms of any serious adverse reaction; in addition, avoid use of fluoroquinolones, in patients who have experienced any serious adverse reactions associated with fluoroquinolones (see Black Box Warnings) Peripheral neuropathy: sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias, and weakness reported; peripheral neuropathy may occur rapidly after initiating and may potentially become permanent In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal impairment; superinfections may occur with prolonged or repeated antibiotic therapy; discontinue use immediately if signs and symptoms of hepatitis occur Not first drug of choice in pediatrics (except in anthrax), because of increased incidence of adverse events in comparison with control subjects, including arthropathy; no data exist on dosing for pediatric patients with renal impairment (ie, Cr Cl Distributed widely throughout body; tissue concentrations often exceed serum concentrations, especially in kidneys, gallbladder, liver, lungs, gynecologic tissue, and prostatic tissue; cerebrospinal fluid (CSF) concentration is 10% in noninflamed meninges and 14-37% in inflamed meninges; crosses placenta; enters breast milk Protein bound: 20-40% Vd: 2.1-2.7 L/kg Additive: Aminophylline, amoxicillin, amoxicillin-clavulanate, amphotericin, ampicillin-sulbactam, ceftazidime, cefuroxime, clindamycin, floxacillin, heparin, piperacillin, sodium bicarbonate, ticarcillin Y-site: Aminophylline, ampicillin-sulbactam, azithromycin, cefepime, dexamethasone sodium phosphate, furosemide, heparin, hydrocortisone sodium succinate, magnesium sulfate(? ), methylprednisolone sodium succinate, phenytoin, potassium phosphates, propofol, sodium bicarbonate(? ), sodium phosphates, total parenteral nutrition formulations, warfarin Solution: Compatible with most IV fluids Additive: Amikacin, aztreonam, dobutamine, dopamine, fluconazole, gentamicin, lidocaine, linezolid, metronidazole (ready-to-use form is compatible; hydrochloride form in vial is incompatible), midazolam, potassium chloride, tobramycin Y-site: Amiodarone, calcium gluconate, clarithromycin, digoxin, diphenhydramine, dobutamine, dopamine, linezolid, lorazepam, midazolam, promethazine, quinupristin/dalfopristin, tacrolimus The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. IV: 400 mg IV every 12 hours Oral: 500 mg orally every 12 hours Duration of therapy: 60 days Comments: -Therapy should be started as soon as possible after suspected/confirmed exposure. Use: For treatment of inhalational anthrax (postexposure) to reduce incidence/progression of disease after exposure to aerosolized Bacillus anthracis US CDC recommendations: -IV: 400 mg IV every 8 hours -Oral: 500 mg orally every 12 hours Duration of Therapy: Postexposure prophylaxis for B anthracis infection: 60 days Systemic anthrax: -With possible/confirmed meningitis: At least 2 to 3 weeks or until patient is clinically stable (whichever is longer) -When meningitis has been excluded: At least 2 weeks or until patient is clinically stable (whichever is longer) -Patients exposed to aerosolized spores will require prophylaxis to complete an antimicrobial regimen of 60 days from onset of illness. Cutaneous anthrax without systemic involvement: -Bioterrorism-related cases: 60 days -Naturally acquired cases: 7 to 10 days Comments: -The preferred drug for pregnant women -Recommended as a preferred oral drug for postexposure prophylaxis and for the treatment of cutaneous anthrax without systemic involvement -Recommended as the preferred IV drug for the treatment of systemic anthrax -Recommended for all strains (regardless of penicillin susceptibility or if susceptibility unknown) when used for postexposure prophylaxis, systemic anthrax when meningitis has been excluded, or cutaneous anthrax without systemic involvement -Recommended for use with a protein synthesis inhibitor when used for systemic anthrax; the addition of a bactericidal beta-lactam is recommended with possible/confirmed meningitis. -Systemic anthrax includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck. -Current guidelines should be consulted for additional information. IV: 400 mg IV every 12 hours Oral: 500 mg orally every 12 hours Duration of therapy: 60 days Comments: -Therapy should be started as soon as possible after suspected/confirmed exposure. Use: For treatment of inhalational anthrax (postexposure) to reduce incidence/progression of disease after exposure to aerosolized Bacillus anthracis US CDC recommendations: -IV: 400 mg IV every 8 hours -Oral: 500 mg orally every 12 hours Duration of Therapy: Postexposure prophylaxis for B anthracis infection: 60 days Systemic anthrax: -With possible/confirmed meningitis: At least 2 to 3 weeks or until patient is clinically stable (whichever is longer) -When meningitis has been excluded: At least 2 weeks or until patient is clinically stable (whichever is longer) -Patients exposed to aerosolized spores will require prophylaxis to complete an antimicrobial regimen of 60 days from onset of illness. Cutaneous anthrax without systemic involvement: -Bioterrorism-related cases: 60 days -Naturally acquired cases: 7 to 10 days Comments: -The preferred drug for pregnant women -Recommended as a preferred oral drug for postexposure prophylaxis and for the treatment of cutaneous anthrax without systemic involvement -Recommended as the preferred IV drug for the treatment of systemic anthrax -Recommended for all strains (regardless of penicillin susceptibility or if susceptibility unknown) when used for postexposure prophylaxis, systemic anthrax when meningitis has been excluded, or cutaneous anthrax without systemic involvement -Recommended for use with a protein synthesis inhibitor when used for systemic anthrax; the addition of a bactericidal beta-lactam is recommended with possible/confirmed meningitis. -Systemic anthrax includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck.

Short-course ciprofloxacin treatment of acute uncomplicated urinary.
Short-course ciprofloxacin treatment of acute uncomplicated urinary.

The Urinary Tract Infection Study Group corrected. to determine the minimum effective dosing regimen of ciprofloxacin for the treatment of acute, symptomatic. Ciprofloxacin Cipro is an antibiotic used to treat or prevent infections caused by various bacteria that are sensitive toCiprofloxacin. DRUGS. Basics. Side Effects. Interactions. Dosage.

Cipro uti dosage
Rating 4,7 stars - 314 reviews